CD134 Monoklonaler Antikörper

CD134 Monoklonal Antikörper für FC

Wirt / Isotyp

Ratte / IgG1, kappa

Getestete Reaktivität

Maus

Anwendung

FC

Konjugation

Unkonjugiert

CloneNo.

OX-86

Kat-Nr. : 65136-1-Ig

Synonyme

ACT35, CD134, Ly 70, Ox40, Tnfrsf4, Txgp1, TXGP1L

---

Galerie der Validierungsdaten

• 

  FC experiment of BALB/c mouse splenocytes using 65136-1-Ig

  1X10^6 Con-A stimulated BALB/c mouse splenocytes were surface stained with CoraLite® Plus 647 Anti-Mouse CD3 (CL647-65077, Clone: 17A2), 1 ug Anti-Mouse CD134 (65136-1-Ig, Clone: OX-86) or rat IgG1 isotype control, and FITC anti-rat IgG1 Antibody at dilution 1:100. Cells were not fixed.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in FC: Con-A stimulated mouse splenocytes

Empfohlene Verdünnung

Anwendung	Verdünnung
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Produktinformation

65136-1-Ig bindet in FC CD134 und zeigt Reaktivität mit Maus

• Getestete Reaktivität: Maus
• Wirt / Isotyp: Ratte / IgG1, kappa
• Klonalität: Monoklonal
• Typ: Antikörper
• Immunogen: k.A.
• Vollständiger Name: tumor necrosis factor receptor superfamily, member 4
• GenBank-Zugangsnummer: BC065782
• Gene symbol: Tnfrsf4
• Gene ID (NCBI): 22163
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Affinitätsreinigung
• Lagerungspuffer: PBS with 0.09% sodium azide.
• Lagerungsbedingungen: Store at 2-8°C. Stable for one year after shipment.

Hintergrundinformationen

CD134, also known as OX40 and TNFRSF4, is a member of the TNFR-superfamily of receptors (PMID: 2828930; 9766631). It is a type I transmembrane protein predominantly expressed on activated T cells which include CD4 and CD8 T cells, Th2, Th1, and Th17 cells, as well as regulatory T cells (Tregs) (PMID: 20307208). CD134 is activated by its cognate ligand CD134L (OX40L) and functions as a T cell co-stimulatory molecule (PMID: 26215166). CD134-CD134L interactions have been proposed as a potential therapeutic target for treating autoimmune diseases, cancer and infectious disease (PMID: 26215166; 19426222).